301 related articles for article (PubMed ID: 34392614)
21. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
22. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
[TBL] [Abstract][Full Text] [Related]
23. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
24. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling.
Xie W; Zhang Y; Wang B; Hu Y; Zhan B; Wei F; Tang J; Lian J
Cancer Med; 2020 Sep; 9(17):6367-6376. PubMed ID: 32677374
[TBL] [Abstract][Full Text] [Related]
25. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
[TBL] [Abstract][Full Text] [Related]
26. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
27. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
28. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
29. Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
Ge LP; Jin X; Yang YS; Liu XY; Shao ZM; Di GH; Jiang YZ
Oncogene; 2021 Mar; 40(12):2323-2334. PubMed ID: 33654196
[TBL] [Abstract][Full Text] [Related]
30. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer.
Shah VV; Duncan AD; Jiang S; Stratton SA; Allton KL; Yam C; Jain A; Krause PM; Lu Y; Cai S; Tu Y; Zhou X; Zhang X; Jiang Y; Carroll CL; Kang Z; Liu B; Shen J; Gagea M; Manu SM; Huo L; Gilcrease M; Powell RT; Guo L; Stephan C; Davies PJ; Parker-Thornburg J; Lozano G; Behringer RR; Piwnica-Worms H; Chang JT; Moulder SL; Barton MC
Nat Commun; 2021 Sep; 12(1):5389. PubMed ID: 34508101
[TBL] [Abstract][Full Text] [Related]
31. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression.
Li K; Zhang TT; Wang F; Cui B; Zhao CX; Yu JJ; Lv XX; Zhang XW; Yang ZN; Huang B; Li X; Hua F; Hu ZW
Oncogene; 2018 May; 37(22):2967-2981. PubMed ID: 29520103
[TBL] [Abstract][Full Text] [Related]
32. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
33. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
34. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
[TBL] [Abstract][Full Text] [Related]
35. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
37. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
38. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
